2024
Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC
Panja S, Truica M, Yu C, Saggurthi V, Craige M, Whitehead K, Tuiche M, Al-Saadi A, Vyas R, Ganesan S, Gohel S, Coffman F, Parrott J, Quan S, Jha S, Kim I, Schaeffer E, Kothari V, Abdulkadir S, Mitrofanova A. Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Nature Communications 2024, 15: 352. PMID: 38191557, PMCID: PMC10774320, DOI: 10.1038/s41467-024-44686-5.Peer-Reviewed Original Research
2023
Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
Kim I. Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT. Investigative And Clinical Urology 2023, 64: 310-311. PMID: 37417555, PMCID: PMC10330420, DOI: 10.4111/icu.20230178.Peer-Reviewed Original Research
2022
Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve
Kim J, Kaldany A, Lichtbroun B, Singer E, Jang T, Ghodoussipour S, Kim M, Kim I. Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve. Journal Of Endourology 2022, 36: 1285-1289. PMID: 35906798, PMCID: PMC9587764, DOI: 10.1089/end.2021.0885.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyShort-term outcomesCase seriesRadical prostatectomyAcceptable short-term outcomesSurgeon 2Average prostate weightLearning curveMedian patient ageClavien-Dindo scaleMedian operating timeTotal postoperative complicationsShorter hospital stayLarge case seriesOperating timeProstate-specific antigenRobotic radical prostatectomyInstitutional review boardSignificant learning curveHospital stayMedian followPostoperative complicationsIntraoperative complicationsPerioperative outcomesBlood lossUntargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome
Ma Y, Zheng Z, Xu S, Attygalle A, Kim I, Du H. Untargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome. Analyst 2022, 147: 3043-3054. PMID: 35642979, DOI: 10.1039/d2an00676f.Peer-Reviewed Original ResearchConceptsAtmospheric pressure chemical ionization mass spectrometryPressure chemical ionization mass spectrometryChemical ionization mass spectrometryMass spectrometryLaser diode thermal desorptionIonization mass spectrometryMass/charge ratioMass spectroscopyChemical profilingBackbone fragmentsCharge ratioThermal desorptionSpectrometryMetabolite profilingPeak intensityUrine metabolite profilingUrine samplesSpectroscopyIonsDesorptionHereinUrine metabolitesMultivariate statistical analysisSurvival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis
Srivastava A, Patel H, Koehne E, Gupta G, Drachtman R, Pierorazio P, Bagrodia A, Elsamra S, Kim I, Ghodoussipour S, Singer E, Jang T, Patel H, Barone J. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis. Urologic Oncology Seminars And Original Investigations 2022, 40: 169.e1-169.e12. PMID: 35144865, PMCID: PMC8960351, DOI: 10.1016/j.urolonc.2021.12.012.Peer-Reviewed Original ResearchConceptsNonseminomatous germ cell tumorsCancer-specific survivalGerm cell tumorsCell tumorsStage groupPediatric patientsAdolescent patientsYoung adultsStage IAdvanced nonseminomatous germ cell tumorsSurvival analysisAge groupsWorse cancer-specific survivalCox proportional hazards modelTesticular germ cell tumorsEnd Results (SEER) databaseExcellent survival outcomesStage III tumorsExcellent oncologic outcomesImportant prognostic factorKaplan-Meier curvesCommon solid malignancyProportional hazards modelNSGCT patientsOncologic outcomesAssociation of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer
Patel H, Srivastava A, Kim S, Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. Journal Of Urology 2022, 207: 1057-1066. PMID: 34978466, DOI: 10.1097/ju.0000000000002369.Peer-Reviewed Original ResearchConceptsPrimary retroperitoneal lymph node dissectionRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsLymph node countLymph nodesOverall survivalTherapeutic implicationsTesticular nonseminomatous germ cell tumorsFive-year OS ratesHigher lymph node countLymph node-positive diseasePrimary retroperitoneal lymphadenectomyClinical stage INational Cancer DatabaseLymph node dissectionNode-positive diseaseKaplan-Meier methodNonseminomatous testicular cancerCS IGerm cell tumorsLogistic regression analysisNode countImproved OSNode dissectionRetroperitoneal lymphadenectomy
2021
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonthsComparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series
Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. Journal Of Urology 2021, 206: 1184-1191. PMID: 34181471, DOI: 10.1097/ju.0000000000001939.Peer-Reviewed Original ResearchConceptsRobotic-assisted radical prostatectomyAssisted radical prostatectomyConsole timeRadical prostatectomyPrimary treatmentStereotactic body radiation therapyFeasible salvage optionNonsurgical primary treatmentPostoperative pad useUrinary function outcomesRisk of incontinenceKaplan-Meier curvesBody radiation therapyProportional hazards modelLonger console timeT-testStudent's t-testPostoperative complicationsMedian followupOncologic outcomesPerioperative dataBlood lossComplication rateSalvage optionFunction outcomesEffects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy
Lee G, Nagaya N, Desantis J, Madura K, Sabaawy H, Kim W, Vaz R, Cruciani G, Kim I. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. Molecular Cancer Therapeutics 2021, 20: 490-499. PMID: 33277442, DOI: 10.1158/1535-7163.mct-20-0417.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerSecond-line antiandrogen therapyAR full lengthAndrogen receptor splice variant 7AR-V7Antiandrogen therapyAndrogen-responsive prostate cancer cellsProstate cancer cellular proliferationHuman prostate cancer cell linesProstate cancer cell linesStandard of careCancer cellular proliferationCellular proliferationPotential therapeutic valueProstate cancer cellsAgents abirateroneCancer cell linesProteolysis Targeting ChimerasMechanisms of resistanceAndrogen receptorAR DNAProstate cancerTumor growthTherapeutic valueAntiproliferative effectsRelationship communication and the course of psychological outcomes among couples coping with localised prostate cancer
Manne S, Kashy D, Myers‐Virtue S, Zaider T, Kissane D, Heckman C, Kim I, Penedo F, Lee D. Relationship communication and the course of psychological outcomes among couples coping with localised prostate cancer. European Journal Of Cancer Care 2021, 30: e13401. PMID: 33586282, PMCID: PMC9165020, DOI: 10.1111/ecc.13401.Peer-Reviewed Original ResearchConceptsBetter psychological outcomesPsychological outcomesPoor psychological outcomesRelationship communicationCancer-specific distressMeasures of communicationMutual avoidancePsychological adjustmentCommunication variablesCommunication trainingCancer concernsEffective interventionsGood communicationDepressive symptomsHigher disclosureProstate cancerImportant predictorPredictive rolePositive standingAvoidancePositive directionProstate cancer patientsSpousesMore researchGreater focus
2020
Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture
Goodin S, Kim I, Lee M, Shih W, Orlick M, Zheng X, Yang C. Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture. Nutrition And Cancer 2020, 73: 2740-2750. PMID: 33319628, PMCID: PMC8670097, DOI: 10.1080/01635581.2020.1857412.Peer-Reviewed Original ResearchConceptsVitamin E mixtureProstate tissue levelsUrine samplesReported adverse eventsDay of surgeryProstate cancer patientsPhase 0 trialsDays of supplementationCancer preventive activityAdverse eventsBlood lossTreatment armsUrine levelsCancer patientsRadical prostatectomyAnimal modelsVitamin EProstate tissueTissue levelsPreventive activitiesProstate levelsSupplementationPatientsProstatectomySurgeryTherapeutic prognosis of prostate cancer using surface‐enhanced Raman scattering of patient urine and multivariate statistical analysis
Ma Y, Chi J, Zheng Z, Attygalle A, Kim I, Du H. Therapeutic prognosis of prostate cancer using surface‐enhanced Raman scattering of patient urine and multivariate statistical analysis. Journal Of Biophotonics 2020, 14: e202000275. PMID: 32909380, DOI: 10.1002/jbio.202000275.Peer-Reviewed Original ResearchAbrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation
Kim I, Jang T, Kim S, Modi P, Singer E, Elsamra S, Kim I. Abrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation. Cancer 2020, 126: 5114-5123. PMID: 32888321, DOI: 10.1002/cncr.33179.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceProstate cancerSurvival disparitiesWhite menProstate cancer screening recommendationsBlack menPCa-specific survivalAdverse clinical featuresCancer screening recommendationsEnd Results (SEER) databaseYear of diagnosisProstate-specific antigenClinical featuresScreening recommendationsResults databaseSurvival outcomesGrade CGrade D.White individualsMenRacial discrepanciesSurvivalTask ForceOutcomesTotalThe cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer
Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International 2020, 125: 792-800. PMID: 32176456, DOI: 10.1111/bju.15055.Peer-Reviewed Original ResearchConceptsHormone-sensitive metastatic prostate cancerMetastatic prostate cancerCytoreductive prostatectomyAndrogen deprivation therapyProstate cancerOverall survivalRadical prostatectomyLimited bone metastasesCancer-specific outcomesLocal treatment optionsProgression-free survivalDiagnosis of metastasisPrimary outcome measureNovel treatment algorithmOligometastatic settingAdjuvant treatmentMetastatic settingSecondary endpointsCastration resistanceMetastatic diseaseStandard therapyBone metastasesDefinitive treatmentOngoing trialsTreatment algorithmIndividual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, Lu‐Yao G. Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine 2020, 9: 2379-2389. PMID: 32035002, PMCID: PMC7131852, DOI: 10.1002/cam4.2862.Peer-Reviewed Original ResearchConceptsHigh-risk PCaPCa mortalityCause mortalityPopulation-based retrospective cohort studyHigh-risk prostate cancerCox proportional hazards modelRetrospective cohort studyHigh-risk patientsFirst human studyProstate cancer metastasisCause of deathProportional hazards modelPre-clinical studiesMetformin useCohort studyProstate cancerStatinsHazards modelHuman studiesPatientsMetforminSignificant associationMortalityPropensity scoreCancer metastasisEDITORIAL COMMENT
Sterling J, Jang T, Kim I. EDITORIAL COMMENT. Urology 2020, 135: 122. PMID: 31895674, DOI: 10.1016/j.urology.2019.07.052.Peer-Reviewed Original Research
2019
TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer
Lee G, Rosenfeld J, Kim W, Kwon Y, Palapattu G, Mehra R, Kim W, Kim I. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. PLOS ONE 2019, 14: e0213488. PMID: 31536510, PMCID: PMC6752758, DOI: 10.1371/journal.pone.0213488.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesBeta CateninCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmHumansMaleMiceMice, KnockoutNeuroendocrine CellsNitrilesPhenylthiohydantoinProstatic NeoplasmsProtein BindingProtein TransportTranscription Factor 7-Like 2 ProteinXenograft Model Antitumor AssaysConceptsCastration-resistant prostate cancerEnzalutamide resistanceTranscription factor 4Neuroendocrine differentiationProstate cancerSecond-generation androgen receptor antagonistHuman prostate cancer cell linesLNCaP human prostate cancer cell lineResistant prostate cancerProstate cancer cell linesStandard of careAndrogen receptor antagonistMouse xenograft modelExpression levelsCell linesTCF4 overexpressionCancer cell linesMedian timeClinical benefitReceptor antagonistNeuroendocrine markersMetastatic CaPTreatment resistanceXenograft modelParental cell lineDihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL
Lee G, Kim J, Kwon S, Stein M, Hong J, Nagaya N, Billakanti S, Kim M, Kim W, Kim I. Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL. Endocrinology 2019, 160: 2049-2060. PMID: 31184711, PMCID: PMC6691685, DOI: 10.1210/en.2019-00367.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyCell linesHuman peripheral blood monocytesMetastatic prostate cancerPotential treatment optionPeripheral blood monocytesCytotoxicity of macrophagesHuman monocyte cell lineProstate cancer cellsCaP cell linesMonocyte cell lineVivo mouse studiesCytotoxic activityMurine macrophage cell lineApoptosis-inducing ligandConcentration-dependent mannerDeprivation therapyClodronate liposomesTreatment optionsM1 polarizationCaP tumorsAndrogen receptorMacrophage cell lineProstate cancerImmune responseDNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome
Na J, Nagaya N, Rha K, Han W, Kim I. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome. Clinical Genitourinary Cancer 2019, 17: 299-305.e1. PMID: 31204211, DOI: 10.1016/j.clgc.2019.05.004.Peer-Reviewed Original ResearchConceptsClear cell renal cell carcinomaDisease-free survivalAdvanced clear cell renal cell carcinomaDDR pathway alterationPathway alterationsLocalized Clear Cell Renal Cell CarcinomaDecreased disease-free survivalTCGA databaseShorter disease-free survivalCopy number alterationsTherapeutic agentsCox regression analysisT3-4 diseaseClear-Cell RenalRenal cell carcinomaDDR pathwaysPresence of mutationsT3a diseaseNeoadjuvant therapyOverall survivalPoor outcomeCell carcinomaCommon subtypeDisease progressionKidney cancerSimilar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology 2019, 19: 33. PMID: 31060606, PMCID: PMC6501301, DOI: 10.1186/s12894-019-0453-9.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerDDR pathway alterationProstate cancerPathway alterationsMetastatic castration-resistant prostate cancerSerum prostate-specific antigenHigh-risk diseaseMetastatic prostate cancerLower overall survivalPathway gene mutationsProstate-specific antigenPotential therapeutic targetUnited States National Cancer InstituteNational Cancer InstituteCRPC patientsCancer Genome AtlasOverall survivalSimilar incidenceTumor stageUnivariate analysisCancer InstituteTherapeutic targetSpecific antigenPARP inhibitorsPathway status